The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
Open accessAbstract
BACKGROUND: Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it is associated with inappropriate activation of mammalian target of rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis. Sirolimus (also called rapamycin) inhibits mTOR and has shown promise in phase 1-2 trials involving patients with LAM. METHODS: We conducted a two-stage trial of sirolimus involving 89 patients with LAM who had moderate lung impairment--a 12-month randomized, double-blind comparison of sirolimus with placebo, followed by a 12-month observation period. The primary end point was the difference between the groups in the rate of change (slope) in forced expiratory volume in 1 second (FEV(1)). RESULTS: During the treatment period, the FEV(1) slope was -12±2 ml per month in the placebo group (43 patients) and 1±2 ml per month in the sirolimus group (46 patients) (P<0.001). The absolute between-group difference in the mean change in FEV(1) during the treatment period was 153 ml, or approximately 11% of the mean FEV(1) at enrollment. As compared with the placebo group, the sirolimus group had improvement from baseline to 12 months in measures of forced vital capacity, functional residual capacity, serum vascular endothelial growth factor D (VEGF-D), and quality of life and functional performance. There was no significant between-group difference in this interval in the change in 6-minute walk distance or diffusing capacity of the lung for carbon monoxide. After discontinuation of sirolimus, the decline in lung function resumed in the sirolimus group and paralleled that in the placebo group. Adverse events were more common with sirolimus, but the frequency of serious adverse events did not differ significantly between the groups. CONCLUSIONS: In patients with LAM, sirolimus stabilized lung function, reduced serum VEGF-D levels, and was associated with a reduction in symptoms and improvement in quality of life. Therapy with sirolimus may be useful in selected patients with LAM. (Funded by the National Institutes of Health and others; MILES ClinicalTrials.gov number, NCT00414648.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although exposure to mTOR inhibitors in the immediate post-transplant period has been associated with delayed bronchial anastomotic healing or anastomotic dehiscence, mTOR inhibitors are now successfully continued up until the time transplant in many centers without complications.(305, 315, 320)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [315]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although exposure to mTOR inhibitors in the immediate post-transplant period has been associated with delayed bronchial anastomotic healing or anastomotic dehiscence, mTOR inhibitors are now successfully continued up until the time transplant in many centers without complications.(305, 315, 320)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [315]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
Sengupta, S., Peterson, T. R., & Sabatini, D. M. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.026 · Cited by 1,275
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,250
Self-citationKwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 674
Carsillo, T., Astrinidis, A., & Henske, E. P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.11.6085 · Cited by 648
Minimal Clinically Important Differences in COPD Lung Function
Donohue, J. F. (2005) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200053377 · Cited by 525
The truly remarkable universality of half a standard deviation: confirmation through another look
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2004) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.4.5.581 · Cited by 490
The NHLBI Lymphangioleiomyomatosis Registry
Ryu, J. H., Moss, J., Beck, G. J., Lee, J.-C., Brown, K. K., Chapman, J. T., Finlay, G. A., Olson, E. J., Ruoss, S. J., MAURER, J. R., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200409-1298oc · Cited by 466
Self-citationTuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation
Goncharova, E., Goncharov, D. A., Eszterhas, A., Hunter, D., Glassberg, M., Yeung, R. S., Walker, C., Noonan, D., Kwiatkowski, D., Chou, M. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202678200 · Cited by 433
Pulmonary Lymphangioleiomyomatosis: A Study of 69 Patients
Urban, T., Lazor, R., Lacronique, J., Murris, M., Labrune, S., & Valeyre, D. (1999) · Medicine · doi:10.1097/00005792-199909000-00004 · Cited by 327
McCormack, F. X. (2008) · CHEST Journal · doi:10.1378/chest.07-0898 · Cited by 303
Self-citation
Research works printed but not linked: 1
- Khanna D, 2010, Clin Exp Rheumatol, 28, S55
Cited by
Sorted by citations
Items 401–500 of 999
Wu, X., Xu, W., Wang, J., Tian, X., Tian, Z., & Xu, K. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0634-z · Cited by 17
Recent advances in the pathobiology and clinical management of lymphangioleiomyomatosis
Harari, S. A., Spagnolo, P., Cocconcelli, E., Luisi, F., & Cottin, V. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000502 · Cited by 17
Wang, W., Guo, H., Shi, B., Sun, H., Li, H., Zhang, Y., & Cai, Y. (2019) · International Urology and Nephrology · doi:10.1007/s11255-019-02093-6 · Cited by 17
Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis
Burger, C. D. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1106358 · Cited by 17
Baldi, B. G., Samano, M. N., Campos, S. V., de Oliveira, M. R., Junior, J. E. A., Carraro, R. M., Teixeira, R. H. O. B., Minguini, I. P., Burlina, R., Pato, E. Z. S., et al. (2017) · Lung · doi:10.1007/s00408-017-0045-y · Cited by 16
Agarwal, S., Anderson, B. K., Mahajan, P., Fernandes, C. J., Margolin, J., & Iacobas, I. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29510 · Cited by 16
Gynecologic perivascular epithelioid cell tumors (PEComas): a review of recent evidence
Levin, G., Capella, M. P., Meyer, R., Brezinov, Y., & Gotlieb, W. H. (2024) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-024-07510-5 · Cited by 16
T Cells and Lung Injury. Impact of Rapamycin
Nakajima, T., Lin, K., Li, J., McGee, H. S., Kwan, J. M., Perkins, D. L., & Finn, P. W. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0171oc · Cited by 16
Current management of lymphangioleiomyomatosis
Taillé, C., Borie, R., & Crestani, B. (2011) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328349ac8c · Cited by 16
Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells
Valianou, M., Filippidou, N., Johnson, D. L., Vogel, P., Zhang, E. Y., Liu, X., Lu, Y., Yu, J. J., Bissler, J. J., & Astrinidis, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-39418-5 · Cited by 16
Possible Novel Therapeutic Targets in Lymphangioleiomyomatosis Treatment
Song, X., Cai, H., Yang, C., Xue, X., Wang, J., Mo, Y., Zhu, M., Zhu, G., Ye, L., & Jin, M. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.554134 · Cited by 16
Lymphangioleiomyomatosis in a Male
Wakida, K., Watanabe, Y., Kumasaka, T., Seyama, K., Mitani, K., Hiraki, T., Kamimura, G., Nagata, T., Nakamura, Y., & Sato, M. (2015) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2014.11.069 · Cited by 16
The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
Courtwright, A., Goldberg, H. J., Henske, E. P., & El‐Chemaly, S. (2017) · European Respiratory Review · doi:10.1183/16000617.0004-2016 · Cited by 16
Self-citationChordoma Occurs in Young Children With Tuberous Sclerosis
Dahl, N. A., Luebbert, T., Loi, M. M., Neuberger, I., Handler, M. H., Kleinschmidt-DeMasters, B. K., & Levy, J. M. M. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx032 · Cited by 16
Johnson, J., & Johnson, S. R. (2019) · Thorax · doi:10.1136/thoraxjnl-2019-213338 · Cited by 16
Salman, J., Ius, F., Sommer, W., Siemeni, T., Fleissner, F., Alhadidi, H., Kugler, C., Avsar, M., Haverich, A., Warnecke, G., et al. (2019) · Progress in Transplantation · doi:10.1177/1526924819835815 · Cited by 15
Kurosaki, T., Otani, S., Miyoshi, K., Okazaki, M., Sugimoto, S., Suno, M., Yamane, M., Kobayashi, M., Oto, T., & Toyooka, S. (2020) · The Clinical Respiratory Journal · doi:10.1111/crj.13108 · Cited by 15
New insights into spontaneous pneumothorax: A review
Louw, E. H., Shaw, J., & Koegelenberg, C. (2021) · African Journal of Thoracic and Critical Care Medicine · doi:10.7196/ajtccm.2021.v27i1.054 · Cited by 17
Lung transplantation for lymphangioleiomyomatosis
Warrior, K., & Dilling, D. F. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.09.021 · Cited by 15
Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1
Du, H., Yang, Y. C., Liu, H.-J., Yuan, M., Asara, J. M., Wong, K., Henske, E. P., Singh, M., & Kwiatkowski, D. J. (2023) · Journal of Clinical Investigation · doi:10.1172/jci167861 · Cited by 15
Nursing Implications for the Lifelong Management of Tuberous Sclerosis Complex
Agricola, K. D., Tudor, C., Krueger, D. A., & Franz, D. N. (2013) · Journal of Neuroscience Nursing · doi:10.1097/jnn.0b013e3182986146 · Cited by 15
Positioning Ganglioside D3 as an Immunotherapeutic Target in Lymphangioleiomyomatosis
Gilbert, E. R., Eby, J. M., Hammer, A. M., Klarquist, J. S., Christensen, D. G., Barfuss, A. J., Boissy, R. E., Picken, M. M., Love, R. B., Dilling, D. F., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.04.002 · Cited by 15
Liu, F., Lunsford, E. P., Tong, J., Ashitate, Y., Gibbs, S. L., Yu, J. J., Choi, H. S., Henske, E. P., & Frangioni, J. V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038589 · Cited by 15
Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial
El‐Chemaly, S., Taveira‐DaSilva, A. M., Bagwe, S., Klonowska, K., Machado, T. R., Lamattina, A. M., Goldberg, H. J., Jones, A. M., Julien-Williams, P. A., Maurer, R., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02370-2019 · Cited by 15
Self-citationClinical management of tuberous sclerosis complex over the lifetime of a patient
Frost, M., & Hulbert, J. C. (2015) · Pediatric Health Medicine and Therapeutics · doi:10.2147/phmt.s67342 · Cited by 15
Efficacy of Sirolimus Therapy for Chylous Effusions in Lymphangioleiomyomatosis
Barrera, P., Simons, S. O., Luijk, B., Wessels, M. J. C., & Heijdra, Y. F. (2013) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201212-125oc · Cited by 15
“Getting stuck with LAM”: patients perspectives on living with Lymphangioleiomyomatosis
Belkin, A., Albright, K., Fier, K., Desserich, J. A., & Swigris, J. J. (2014) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-12-79 · Cited by 15
TSC2 modulates cell adhesion and migration via integrin-α1β1
Moir, L. M., Black, J. L., & Krymskaya, V. P. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00414.2011 · Cited by 15
Carlin, D., Golden, J. P., Mogha, A., Samineni, V. K., Monk, K. R., Gereau, R. W., & Cavalli, V. (2018) · eNeuro · doi:10.1523/eneuro.0436-17.2018 · Cited by 15
Quantitative CT analysis of small pulmonary vessels in lymphangioleiomyomatosis
Ando, K., Tobino, K., Kurihara, M., Kataoka, H., Doi, T., Hoshika, Y., Takahashi, K., & Seyama, K. (2012) · European Journal of Radiology · doi:10.1016/j.ejrad.2012.05.033 · Cited by 15
Taveira‐DaSilva, A. M., Julien-Williams, P. A., Jones, A. M., Stylianou, M. P., & Moss, J. (2018) · European Respiratory Journal · doi:10.1183/13993003.02258-2017 · Cited by 15
Self-citationHarari, S. A., Torre, O., Elia, D., Caminati, A., Pelosi, G., Specchia, C., Zompatori, M., & Cassandro, R. (2021) · Respiration · doi:10.1159/000516330 · Cited by 14
Diagnostic performance of VEGF-D for lymphangioleiomyomatosis: a meta-analysis
Li, M., Zhu, W., Wang, J., Yang, X.-D., Li, W.-M., & Wang, G. (2022) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20210337 · Cited by 13
Impact of Age, Menopause, and Sirolimus on Spontaneous Pneumothoraces in Lymphangioleiomyomatosis
Cortinas, N., Liu, J., Kopras, E. J., Memon, H. A., Burkes, R. M., & Gupta, N. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.05.036 · Cited by 14
Liu, L., Dehner, C. A., Grandhi, N., Lyu, Y., Borcherding, D. C., Chrisinger, J. S. A., Zhang, X., Luo, J. R., Tao, Y., Parkes, A. M., et al. (2022) · Genes · doi:10.3390/genes13111932 · Cited by 14
Elia, D., Cassandro, R., Caminati, A., Luisi, F., & Harari, S. A. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104173 · Cited by 14
Ng, L. Y., McGuinness, J. G., Prendiville, T. W., Franklin, O., Walsh, M., Kenny, D. P., Nölke, L., & McMahon, C. J. (2024) · Pediatric Cardiology · doi:10.1007/s00246-024-03420-0 · Cited by 14
Sirolimus for kaposiform hemangioendothelioma: Potential mechanisms of action and resistance
Qiu, T., Xiang, S., Zhou, J., Yang, M. J., Lan, Y., Zhang, X., Gong, X., Zhang, Z., & Ji, Y. (2024) · International Journal of Cancer · doi:10.1002/ijc.35207 · Cited by 16
PEComas: A review of imaging and clinical features
Kinzel, A., McArthur, M., Gettle, L. M., Felker, E. R., & Patel, M. K. (2024) · Clinical Imaging · doi:10.1016/j.clinimag.2024.110332 · Cited by 14
Stepanova, V. V., Дергилев, К. В., Holman, K. R., Parfyonova, Y. V., Цоколаева, З. И., Teter, M., Atochina‐Vasserman, E. N., Volgina, A., Zaitsev, S. V., Lewis, S. P., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.799593 · Cited by 13
Marques, R., Belousova, E., Benedik, M. P., Carter, T., Cottin, V., Curatolo, P., Dahlin, M. G., D’Amato, L., d’Augères, G. B., de Vries, P. J., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01144 · Cited by 14
Pulmonary Lymphangioleiomyomatosis: A Case Report and Literature Review.
Sathirareuangchai, S., Shimizu, D. M., & Vierkoetter, K. R. (2020) · PubMed Central · Cited by 14
Prosdocimi, M., Zuccato, C., Cosenza, L. C., Borgatti, M., Lampronti, I., Finotti, A., & Gambari, R. (2022) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17845.3 · Cited by 14
Faehling, M., Wienhausen-Wilke, V., Fallscheer, S., Trinajstic-Schulz, B., Weber, J., & Leschke, M. (2015) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 14
Extrapulmonary lymphangioleiomyomatosis: a wolf in sheep's clothing
Derweduwen, A. M., Verbeken, E. K., Stas, M., Verschakelen, J., Coolen, J., Verleden, G. M., & Wuyts, W. A. (2012) · Thorax · doi:10.1136/thoraxjnl-2012-201973 · Cited by 14
Regulation of Ras signaling and function by plasma membrane microdomains
Goldfinger, L. E., & Michael, J. V. (2017) · BioScience Trends · doi:10.5582/bst.2016.01220 · Cited by 14
Brakemeier, S., Vogt, L., Adams, L. C., Zukunft, B., Diederichs, G., Hamm, B., Budde, K., & Makowski, M. R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189132 · Cited by 14
Gao, N., Zhang, T., Ji, J., Xu, K., & Tian, X. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0874-7 · Cited by 14
Lymphangioleiomyomatosis: No Longer Ultra-rare
Gupta, N., & Johnson, S. R. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202312-2254ed · Cited by 14
Olatoke, T., Wagner, A., Astrinidis, A., Zhang, E. Y., Guo, M., Zhang, A. G., Mattam, U., Kopras, E. J., Gupta, N., Smith, E. P., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf8549 · Cited by 13
Self-citationProtease activity sensors enable real-time treatment response monitoring in lymphangioleiomyomatosis
Kirkpatrick, J. D., Soleimany, A. P., Dudani, J. S., Liu, H.-J., Lam, H. C., Priolo, C., Henske, E. P., & Bhatia, S. N. (2021) · European Respiratory Journal · doi:10.1183/13993003.00664-2021 · Cited by 13
Lymphangioleiomyomatosis and Other Cystic Lung Diseases
Koslow, M., Lynch, D. A., Cool, C. D., Groshong, S. D., & Downey, G. P. (2023) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2023.01.003 · Cited by 13
Self-citationJohnson, S. R., Shaw, D. E., Avoseh, M., Soomro, I. N., Pointon, K. S., Kokosi, M. A., Nicholson, A. G., Desai, S. R., & George, P. M. (2024) · Thorax · doi:10.1136/thorax-2022-219738 · Cited by 13
Bases moleculares y aplicaciones farmacológicas de la vía de mTOR en dermatología
Salido‐Vallejo, R., Garnacho-Saucedo, G. M., & Vélez, A. (2016) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2015.12.006 · Cited by 13
Koga, T., Hagimori, N., Takemori, S., Morimoto, S., Sumiyoshi, R., Shimizu, T., Hosogaya, N., Fukushima, C., Yamamoto, H., & Kawakami, A. (2020) · Medicine · doi:10.1097/md.0000000000020710 · Cited by 13
Mahi, N. A., Zhang, E. Y., Sherman, S. G., Yu, J. J., & Medvedovic, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094371 · Cited by 13
Johnson, J., Stewart, I. D., & Johnson, S. R. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-217809 · Cited by 13
Tanaka, M., Hirata, H., Wataya‐Kaneda, M., Yoshida, M., & Katayama, I. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.06.003 · Cited by 13
A curious case of acute respiratory distress syndrome
Crawford, T. C., Grimm, J. C., Magruder, J. T., Stephens, R. S., Sciortino, C. M., Vaught, A. “. J., Althaus, J., Shah, A. S., & Kim, B. S. (2015) · Journal of Surgical Case Reports · doi:10.1093/jscr/rjv140 · Cited by 13
Pelvic lymphangioleiomyomatosis treated successfully with everolimus
Wahid, S., Chiang, P. C., Luo, H., Huang, S., Tsai, E., & Chiang, P. (2017) · Medicine · doi:10.1097/md.0000000000004562 · Cited by 13
Kovalenko, A., Sanin, A., Kosmas, K., Zhang, L., Wang, J., Akl, E. W., Giannikou, K., Probst, C. K., Hougard, T. R., Rue, R. W., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2218 · Cited by 13
Lung Transplantation for Interstitial Lung Disease
Whelan, T. P. M. (2012) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.12.003 · Cited by 13
Long-term safety and influence on growth in patients receiving sirolimus: a pooled analysis
Wang, Y., Zou, L., Xu, K., Xu, W., Zhang, M., Lu, Q., Tian, X., Pang, L.-Y., He, W., Wang, Q., et al. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03243-5 · Cited by 13
Witte, M. H., Dellinger, M. T., Papendieck, C. M., & Boccardo, F. M. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9493-1 · Cited by 12
Proapoptotic protein Bim attenuates estrogen-enhanced survival in lymphangioleiomyomatosis
Li, C., Li, N., Liu, X., Zhang, E. Y., Sun, Y., Masuda, K., Li, J., Sun, J. L., Morrison, T. A., Li, X., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86629 · Cited by 12
Sclérose tubéreuse de Bourneville : mise au point
Pfirmann, P., Combe, C., & Rigothier, C. (2021) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2021.03.003 · Cited by 15
Becker, B., & Strowd, R. E., III (2019) · Dermatologic Clinics · doi:10.1016/j.det.2019.05.015 · Cited by 12
Asani, B., Siedlecki, J., Wertheimer, C. M., Liegl, R. G.-H., Wolf, A., Ohlmann, A., Priglinger, S. G., & Priglinger, C. (2022) · BMC Ophthalmology · doi:10.1186/s12886-022-02334-w · Cited by 12
Li, F., Zhang, Y., Lin, Z., Yan, L., Liu, Q., Li, Y., Pei, X., Feng, Y., Han, X., Yang, J., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05511-3 · Cited by 12
Palipana, A., Gecili, E., Song, S., Johnson, S. R., Szczesniak, R. D., & Gupta, N. (2023) · CHEST Journal · doi:10.1016/j.chest.2022.12.027 · Cited by 12
Hurtado-Sierra, D., Garzón, J. X. R., Rojas, L. Z., Fernández-Gómez, Ó., & Manrique-Rincón, F. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1109646 · Cited by 12
Rutkowski, P. L., Przybył, J., & Świtaj, T. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.03.024 · Cited by 12
Tuberous sclerosis complex as a model disease for developing new therapeutics for epilepsy
Jeong, A., & Wong, M. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1151788 · Cited by 12
Elucidation of the mTOR Pathway and Therapeutic Applications in Dermatology
Salido‐Vallejo, R., Garnacho-Saucedo, G. M., & Vélez, A. (2016) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2016.03.001 · Cited by 12
Raimondi, A., Colombo, F., Pintarelli, G., Morosi, C., Renne, S. L., Frezza, A. M., Saponara, M., Tos, A. P. D., Mazzocchi, A., Provenzano, S., et al. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000634 · Cited by 12
Recent advances in the management of lymphangioleiomyomatosis
Xu, K., Tian, X., & Ryu, J. H. (2018) · F1000Research · doi:10.12688/f1000research.14564.1 · Cited by 12
The Role of Interventional Radiologists in the Treatment of Congenital Lymphatic Malformations
Cronan, J. C., Gill, A. E., Shah, J., & Hawkins, C. M. (2020) · Seminars in Interventional Radiology · doi:10.1055/s-0040-1713446 · Cited by 12
Sekimoto, Y., Suzuki, K., Okura, M. K., Hayashi, T., Ebana, H., Kumasaka, T., Mitani, K., Nishino, K., Okamoto, S., Kobayashi, E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85999-5 · Cited by 12
Himes, B. E., Obraztsova, K., Lian, L., Shumyatcher, M., Rue, R. W., Atochina‐Vasserman, E. N., Hur, S. K., Bartolomei, M. S., Evans, J. F., & Krymskaya, V. P. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197105 · Cited by 12
Khaddour, K., Shayuk, M., Ludhwani, D., Gowda, S., & Ward, W. L. (2018) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2018.11.010 · Cited by 12
Camacho‐Magallanes, A., Delaney, S. P., Lian, E. Y., Wiljer, E., Yockell‐Lelièvre, J., Julian, L. M., Pietrobon, A., Batoff, W., Kristof, A. S., & Stanford, W. L. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/683359 · Cited by 12
Recurrence of primary disease following lung transplantation
Esendagli, D. R., Ntiamoah, P., Küpeli̇, E., Bhardwaj, A., Ghosh, S., Mukhopadhyay, S., & Mehta, A. C. (2022) · ERJ Open Research · doi:10.1183/23120541.00038-2022 · Cited by 14
Winden, K. D., Bebin, E. M., Jeste, S., Krueger, D. A., Paul, E., & Sahin, M. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00688-9 · Cited by 12
mTOR Signaling: Recent Progress
Gargalionis, A. N., Papavassiliou, K. A., & Papavassiliou, A. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052587 · Cited by 12
Liu, Y., Gao, Y., Zhao, H., Zhang, M., Duan, M., Li, J., & Zhang, L. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05783-z · Cited by 12
Amosu, M., Jankowski, A. M., McCright, J., Yang, B. E., Fernandez, J. G. D. O., Moore, K. A., Gadde, H. S., Donthi, M., Kaluzienski, M. L., Sriram, V., et al. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2023-0410oc · Cited by 10
mTOR pathway diseases: challenges and opportunities from bench to bedside and the mTOR node
Ritter, L. M., Annear, N. M. P., Baple, E. L., Ben-Chaabane, L. Y., Bódi, I., Brosson, L., Cadwgan, J., Coslett, B., Crosby, A. H., Davies, D. M., et al. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-03740-1 · Cited by 12
A pilot study assessing the effect of bronchodilator on dynamic hyperinflation in LAM
Baldi, B. G., de Albuquerque, A. L. P., Pimenta, S. P., Salge, J. M., Kairalla, R. A., & de Carvalho, C. R. R. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.08.045 · Cited by 11
Takia, L., Jat, K. R., Mandal, A., & Kabra, S. K. (2018) · BMJ Case Reports · doi:10.1136/bcr-2018-226244 · Cited by 11
Monitoring and Managing Patients with Tuberous Sclerosis Complex: Current State of Knowledge
Gomes, I. D. M. E. S., Jesus‐Ribeiro, J., & Palavra, F. (2022) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s266990 · Cited by 11
Sun, Y., Gallacchi, D. A., Zhang, E. Y., Reynolds, S. B., Robinson, L., Malinowska, I. A., Chiou, T. T., Pereira, A. M., Li, C., Kwiatkowski, D. J., et al. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0033oc · Cited by 11
Groft, S. C., & Gopal-Srivastava, R. (2013) · Clinical Investigation · doi:10.4155/cli.13.101 · Cited by 11
Bee, J., Bhatt, R. I., McCafferty, I., & Johnson, S. R. (2015) · Thorax · doi:10.1136/thoraxjnl-2015-207171 · Cited by 11
Feemster, L. C., Lyons, P. G., Chatterjee, R., Kidambi, P., McCormack, F. X., Moss, J., Wilson, K. C., & Thomson, C. C. (2017) · Europe PMC (PubMed Central) · doi:10.1513/annalsats.201609-685cme · Cited by 11
Self-citationCystic Lung Disease in Genetic Syndromes with Deficient Tumor Suppressor Gene Function
Daccord, C., Nicod, L. P., & Lazor, R. (2017) · Respiration · doi:10.1159/000485106 · Cited by 11
Iijima, Y., Fujioka, N., Uchida, Y., Kobayashi, Y., Tsutsui, T., Kakizaki, Y., & Miyashita, Y. (2018) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2018.01.033 · Cited by 11
Lymphangioleiomyomatosis: a case report and review of diagnosis and treatment
Liu, Y., Guo, Z., Zhao, C., Li, X., Liu, H., & Chen, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s161360 · Cited by 11
Li, S., Guan, S., Wang, Y., Cheng, L., Yang, Q., Tian, Z., Zhao, M., Wang, X., & Feng, B. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.04.016 · Cited by 11
Xiang-feng, L., Xu, W., Zhang, L., Zu, Y., Li, Y., Yang, Y., Xiang, Y., Xiang, Y., Chen, L., Liu, W., et al. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-1344-6 · Cited by 11
Machine learning can predict disease manifestations and outcomes in lymphangioleiomyomatosis
Chernbumroong, S., Johnson, J., Gupta, N., Miller, S., McCormack, F. X., Garibaldi, J. M., & Johnson, S. R. (2020) · European Respiratory Journal · doi:10.1183/13993003.03036-2020 · Cited by 11
Self-citation
Metadata
- Authors
- McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., Brown, K. K., Lynch, J. P., Goldberg, H. J., Young, L. R., Kinder, B. W., Downey, G. P., Sullivan, E. J., Colby, T. V., McKay, R. T., Cohen, M. M., Korbee, L., Taveira-DaSilva, A. M., Lee, H.-S., Krischer, J. P., & Trapnell, B. C.
- Affiliations
- University of Cincinnati (US)
- National Hospital Organization (JP)
- National Institutes of Health (US)
- University of Toronto (CA)
- Medical University of South Carolina (US)
- Niigata University Medical and Dental Hospital (JP)
- Oregon Health & Science University (US)
- Cleveland Clinic (US)
- University of Florida (US)
- The University of Texas Health Science Center at Tyler (US)
- National Jewish Health (US)
- Cincinnati Children's Hospital Medical Center (US)
- Harvard University (US)
- United Therapeutics (United States) (US)
- Mayo Clinic (US)
- University of South Florida (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-04-28
- Volume
- 364
- Issue
- 17
- Pages
- 1595-1606
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3118601
- OpenAlex
- W2147028601
- Semantic Scholar
- 0af4a52c455e626ae3c70aa2ba2d64208b19a305
- Cited by
- 1,099
- References
- 27
- Citations by year
- 2026: 38 · 2025: 54 · 2024: 77 · 2023: 70 · 2022: 80 · 2021: 70 · 2020: 72 · 2019: 78 · 2018: 77 · 2017: 65 · 2016: 78 · 2015: 87 · 2014: 71 · 2013: 81 · 2012: 68
- FWCI
- 54.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Tuberous Sclerosis Alliance
- Pfizer
- LAM Foundation
- Cincinnati Children's Hospital Medical Center
- National Institutes of Health (1ul1rr026314-01, 1UL1RR026314)
- U.S. Food and Drug Administration (FD003362, R01 FD003362)
- Canadian Institutes of Health Research
- National Heart, Lung, and Blood Institute (R01HL085453, ZIAHL002541)
- National Center for Research Resources (1UL1 RR-026314-01, U54RR019259, UL1-RR026314, U54RR019498, RR019498, RR019259)
- NHLBI Division of Intramural Research
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Health Sciences › Medicine › Surgery › Vascular Malformations and Hemangiomas
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lymphangioleiomyomatosis, rapamycin, mTOR signaling, lung function, FEV1, VEGF-D, quality of life, adverse events, drug discontinuation, cystic lung disease
- MeSH terms
- Adult, Double-Blind Method, Female, Forced Expiratory Volume, Humans, Middle Aged, Quality of Life, Vital Capacity, Lymphangioleiomyomatosis, Observation, Sirolimus, Medication Adherence, Intention to Treat Analysis, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
